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Abstract X-linked adrenoleukodystrophy (ALD) is a genetic
demyelinating disorder characterized by accumulation of very
long chain fatty acid (VLCFA) in tissues. Lovastatin, an
inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase,
normalizes VLCFA in fibroblasts and plasma from ALD
patients. We dietary treated ALD mice with simvastatin, an
analog of lovastatin with similar pharmacokinetics and effects on
plasma VLCFA in ALD patients at 20 or 60 mg/kg/day for 6^12
weeks. No decrease of VLCFA content was observed in mouse
tissues, including the brain. A significant increase of VLCFA was
rather observed in the brain of ALD mice at 60 mg/kg/
day. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
X-linked adrenoleukodystrophy (ALD) is characterized by
progressive demyelination within the central nervous system,
adrenal insu⁄ciency and accumulation of very long chain
fatty acids (VLCFA) in tissues and plasma due to an impair-
ment of their L-oxidation in peroxisomes [1]. This results from
reduced function of activation of VLCFA to their coenzyme
A (CoA) derivatives [2] that involves a peroxisomal VLCFA-
CoA synthetase and the protein (ALDP) encoded by the ALD
gene. ALDP belongs to a family of ATP-binding cassette
(ABC) hemi-transporters [3] that need to dimerize to exert
their function. Three homologs of ALDP have been identi-
¢ed: the ALD-related (ALDR) protein (66% identity) [4,5],
the more distantly related PMP70 protein (38% identity to
ALDP) [6,7] and the PMP70-related (P70R) protein (27%
identity to ALDP) [8,9]. Using the two-hybrid system and
co-immunoprecipitation, we have recently demonstrated that
ALDP forms homodimers and heterodimers with ALDRP
and PMP70 and identi¢ed missense mutations that abolish
the homo- and heterodimerizations of ALDP [10]. It is how-
ever unclear whether ALDP homodimers or heterodimers
transport VLCFA (or VLCFA-CoA) into peroxisomes or a
substrate necessary to VLACS activation.
The link between VLCFA accumulation and cerebral de-
myelination remains controversial [11]. Studies of phospholip-
id bilayers enriched in VLCFA suggest however that incorpo-
ration of VLCFA in components of the multilamellar myelin
membrane might destabilize ALD myelin [12]. At present, no
satisfactory therapy for ALD is available. Bone marrow trans-
plantation can reverse or stabilize cerebral demyelination,
provided that it is performed at an early stage of the disease
[13]. This procedure is however associated with a high risk of
mortality and has no e¡ect in advanced form of the disease.
Thus, other therapeutic strategies are needed, particularly
those aiming at reducing the accumulation of VLCFA within
the brain from ALD patients.
It was recently shown that lovastatin, a 3-hydroxy-3-meth-
ylglutaryl-CoA reductase inhibitor, suppresses the induction
of inducible nitric oxide synthetase and proin£ammatory cy-
tokines (in particular tumor necrosis factor K) involved in the
pathogenesis of cerebral demyelination in ALD [14]. Lovasta-
tin was also shown to normalize the levels of VLCFA in
¢broblasts [15] an plasma [16] from ALD patients, through
activation of VLCFA oxidation activity. This prompted us to
examine the in vivo e¡ects of simvastatin, an analog of lova-
statin which di¡ers only by the addition of a methyl group, on
the accumulation of VLCFA in tissues from ALD mice.
2. Materials and methods
2.1. Mice and dietary simvastatin treatment
Three to four-month-old ALD male mice and wild-type littermates
on a C57BL/6U129 hybrid background [17] were fed by gavage with
simvastatin at a dose of 20 mg or 60 mg/kg/day for 4 and 12 weeks.
Simvastatin-treated and control groups of wild-type and ALD mice
each consisted of four animals per timepoint. Total plasma cholesterol
was measured by spectrophotometry using the oxidase method [17].
Statistical analyses were done using the Student t-test.
2.2. Analysis of VLCFA concentrations in tissues
Mice were killed by bleeding. Brain, adrenal glands, liver and heart
were frozen and analyzed separately from each mouse. Frozen tissues
were homogenized by sonication. Protein concentration was deter-
mined in aliquot from each sample using the method of Bradford
[18]. VLCFA were then extracted and measured by gas/liquid chro-
matography/mass spectrometry (GLC/MS) as described [19]. [3,3,5,5-
2H4]-Docosanoic (C22:0-d4) and [3,3,5,5-2H4]-hexacosanoic (C26:0-
d4) acids (gift from Dr. H.J. ten Brink, Amsterdam, The Netherlands)
were used as internal standard. Ions at m/z 397, m/z 401, m/z 453 and
m/z 457 corresponding to the [M-57] ions of 22:0, 22:0-d4, 26:0 and
26:0-d4 TBDMS (butyldimethylsilyl) derivatives were selectively
monitored using electron impact. The corresponding peaks were in-
tegrated and the content of C22:0 and C26:0 fatty acids was calcu-
lated according to a calibration curve using C22-d4 and C26-d4 as
internal standards. Results were expressed as C26:0/C22:0 ratios and
Wg/mg protein for C26:0 concentrations. The GLC/MS method used
in this study was previously shown to detect with sensitivity and re-
producibility a di¡erence of 10% in the absolute measure of C26:0 or
C22:0 concentrations [19]. The coe⁄cient of analytical variation was
less than 1.55%. Statistical analyses were done using the Student
t-test.
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3. Results
Treatment with 20 mg/kg/day of simvastatin for 6 or 12
weeks did not lead to signi¢cant di¡erence in body weight
or plasma cholesterol levels of ALD and control wild-type
mice (Table 1). In contrast, treatment with 60 mg/kg/day of
simvastatin led in ALD and control wild-type mice to a 16%
(P6 0.05, Student’s t-test) and 22.5% (P6 0.01) reduced body
weight after respectively 6 and 12 weeks of treatment (Table
1). Plasma cholesterol levels decreased by 18% (P6 0.05) and
31% (P6 0.01) in ALD and control wild-type mice after 6 and
12 weeks of simvastatin treatment (Table 1). No statistically
signi¢cant di¡erences in body weight and plasma cholesterol
levels were observed between ALD and control wild-type mice
on treatment with 20 or 60 mg/kg/day of simvastatin.
Treatment with 20 mg/kg/day of simvastatin for 6 or 12
weeks did not normalize the C26:0 levels and C26:0/C22:0
ratio in brain, adrenal glands, heart and liver from ALD mice
(Fig. 1). In fact, the C26:0 levels increased by 41% (P6 0.01)
and 26% (P6 0.05) in the brain from ALD mice (Fig. 1A)
without changes in the C26:0/C22:0 ratio (Fig. 1B) after treat-
ment for 6 and 12 weeks. No signi¢cant changes of C26:0
levels and C26:0/C22:0 ratio was observed in other tissues.
Treatment with 60 mg/kg/day of simvastatin for 6 weeks
produced an increase of C26:0 levels by 481% in the brain
(P6 0.001), 58% (P6 0.01) in adrenal glands, 74% (P6 0.01)
in the heart and 207% (P6 0.001) in the liver from ALD mice
(Fig. 2A). The C26:0/C22:0 ratio increased by 17% (P6 0.02),
29% (P6 0.01) and 71% (P6 0.001) in brain, adrenal glands
and liver without signi¢cant changes in heart (Fig. 2B), re-
£ecting that simvastatin treatment increased also the C22:0
levels in these tissues. After 12 weeks of treatment, the
C26:0 concentrations decreased but remained higher than at
baseline. The C26:0 levels were still increased by 200%
(P6 0.001), 21.5% (P6 0.02), 87% (P6 0.001) and 46%
(P6 0.01) in brain, adrenal glands, heart and liver from
ALD mice (Fig. 2A). The C26:0/C22:0 ratio was unchanged
in heart and adrenal gland but was increased by 46%
(P6 0.001) and 33% (P6 0.01) in the brain and liver. In con-
trol wild-type mice, treatment with 60 mg/kg/day of simvas-
tatin led to no signi¢cant change in the C26:0/C22:0 ratio
after 6 or 12 weeks of treatment, excepting the adrenal glands
Table 1
E¡ect of simvastatin on total plasma cholesterol and body weight in ALD and control mice
Treatment/duration ALD mice Control mice
cholesterol (mmol/l) weight (g) cholesterol (mmol/l) weight (g)
20 mg/kg/day
untreated (n = 4) 2.83 þ 0.26 22.8 þ 1.0 2.92 þ 0.30 22.5 þ 1.4
6 weeks (n = 4) 2.64 þ 0.22 22.6 þ 1.2 3.06 þ 0.21 21.5 þ 1.7
12 weeks (n = 4) 2.68 þ 0.28 21.8 þ 1.5 2.81 þ 0.31 20.5 þ 1.8
60 mg/kg/day
untreated (n = 4) 2.83 þ 0.26 22.8 þ 1.0 2.92 þ 0.30 22.5 þ 1.4
6 weeks (n = 4) 2.32 þ 0.21a 19.0 þ 2.33a 2.39 þ 0.22a 18.9 þ 2.1a
12 weeks (n = 4) 1.94 þ 0.25b 17.6 þ 1.6b 2.01 þ 0.26b 17.5 þ 1.9b
aP6 0.05.
bP6 0.01.
Fig. 1. C26:0 concentrations (A) and C26:0/C22:0 ratio in brain, adrenal glands, heart and liver from control wild-type (open bars) and ALD
(hatched bars) mice before and after 6 and 12 weeks of simvastatin treatment at 20 mg/kg/day. Each bar represents the mean þ S.D. value of
C26:0 levels or C26:0/C22:0 ratio of four animals. P values are given for tissues showing statistically signi¢cant changes.
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(P6 0.05). The C26:0 levels remained unchanged after 12
weeks of treatment but were increased by 51% (P6 0.01),
49% (P6 0.01), 80% (P6 0.001) and 41% (P6 0.01) in brain,
adrenal glands, heart and liver after 6 weeks of treatment
(Fig. 2A).
Altogether, these data demonstrate that not only simvasta-
tin did not lead to a substantial decrease in VLCFA concen-
tration in tissues from ALD mice at any timepoint but that
simvastatin led to a signi¢cant increase of VLCFA content in
most tissues, particularly within the brain.
4. Discussion
Mice with a targeted disruption in the ALD gene lack a
clinical phenotype but accumulate VLCFA in the brain and
adrenal glands together with a decrease in VLCFA L-oxida-
tion activity in vitro [20^22]. The 3^5-fold accumulation of
VLCFA in the brain from ALD mice is similar to that ob-
served in the brain from ALD patients at an early stage of the
disease. This animal model is therefore suitable to evaluate the
e¡ect of drugs aiming at reducing VLCFA levels within the
brain.
Several compounds were recently shown to lower VLCFA
in ALD ¢broblasts, including 4-phenylbutyrate [23], rolipram
[24] and lovastatin [15]. Lovastatin and other related statins
are most promising because lovastatin was shown to reduce
the plasma levels of VLCFA in ALD patients [16], and statins
are approved for therapeutic usage in hyperlipidemia [25] and
the prevention of coronary heart disease [26]. Lorenzo’s oil, a
dietary therapy enriched in oleic and erucic acids, normalizes
also plasma VLCFA of ALD patients within 4^6 weeks [27].
It has however no e¡ect on the clinical course of the disease,
perhaps because erucic acid, the main active ingredient of
Lorenzo’s oil, does not get into the brain. It is thus essen-
tial to determine whether lovastatin or related statins show
e⁄cacy in experimental models before engaging in human
trials. We decided to evaluate the e¡ect of simvastatin rather
than that of lovastatin because the former drug is more
readily available in di¡erent countries around the world.
Simvastatin and lovastatin have similar pharmacokinetics
and e¡ects on cholesterol metabolism in human and mouse
[28].
Our study demonstrates that simvastatin administered or-
ally at 20 mg/kg/day or 60 mg/kg/day for 6^12 weeks does not
correct the accumulation of VLCFA in the body tissues from
ALD mice, including the brain. The e¡ect of simvastatin on
plasma VLCFA was not studied in ALD mice because this
animal model, in contrast to ALD patients, does not accumu-
late VLCFA in blood. The accumulation of VLCFA in plas-
ma re£ects mainly the impaired capacity of hepatocytes to
degrade them. A possible explanation accounting for the dis-
crepancy between ALD patients and ALD mice is the absence
of ALDP expression in mouse hepatocytes, in contrast to that
observed in human hepatocytes [29]. An other related half-
peroxisomal ABC transporter plays likely the function of
ALDP in mouse hepatocytes.
The lack of e⁄cacy of simvastatin to reduce tissue VLCFA
levels is unlikely due to the requirement of higher doses than
that required for lowering cholesterol levels. A signi¢cant de-
crease in the body weight of ALD and control wild-type mice,
as well as in their plasma cholesterol levels was observed at a
dose of 60 mg/kg/day, which is close to toxic levels.
Insu⁄cient brain distribution of simvastatin could be an
explanation for its absence of e⁄cacy in this tissue. Simvas-
tatin, as lovastatin, is a lipophilic prodrug which undergoes in
vivo transformation into active hydroxy-acid forms [30]. Sim-
vastatin, like lovastatin, is e⁄ciently taken up by hepatocytes
after oral administration [31]. In our experiments, simvastatin
was unable to lower the levels of VLCFA in liver from ALD
mice at 20 or 60 mg/kg/day, despite its high hepato selectivity.
Although the brain selectivity of simvastatin (and lovastatin)
is much less documented, it is therefore unlikely that the lack
Fig. 2. C26:0 concentrations (A) and C26:0/C22:0 ratio in brain, adrenal glands, heart and liver from control wild-type (open bars) and ALD
(hatched bars) mice before and after 6 and 12 weeks of simvastatin treatment at 60 mg/kg/day. Each bar represents the mean þ S.D. value of
C26:0 levels or C26:0/C22:0 ratio of four animals. P values are given for ALD tissues showing statistically signi¢cant changes.
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of e¡ect of simvastatin in brain was due to its low uptake by
this tissue.
Our study demonstrates that simvastatin at 60 mg/kg/day
increased signi¢cantly the levels of C26:0 and at a lesser ex-
tent the levels of C22:0 in most tissues from ALD mice.
VLCFA accumulate predominantly in cholesterol ester frac-
tions in ALD tissues. In normal human monocyte-derived
macrophages loaded with cholesterol, lovastatin was shown
to hinder the delivery of intracellular cholesterol to the plasma
membrane, resulting in increased free cholesterol and lower
levels of cholesteryl esters [32]. In non-loaded cells where vir-
tually all cholesterol is of endogenous origin and normally
translocated to the cell membrane, lovastatin prevented this
process leading to an increase in the concentration of choles-
teryl esters, even free and total cholesterol levels decreased.
This study did not address the e¡ects of lovastatin on VLCFA
but demonstrated that saturated fatty acids were not reduced
in loaded cells whereas unsaturated fatty acids increased at the
highest dose (12 WM/l) of lovastatin in non-cholesterol-loaded
cells. The in vivo intracellular e¡ects of statins on VLCFA
levels might thus critically be dependent on cholesterol load-
ing of cells. The concentration of lovastatin used in these
studies encompassed the plasma levels found in human sub-
jects after standard oral administration and these e¡ects prob-
ably apply to most if not all members of this drug class.
Although a preliminary study showed that lovastatin is able
to normalize plasma VLCFA in ALD patients [16], it must be
emphasized that changes in the plasma levels of VLCFA may
not necessarily re£ect levels of free/bound VLCFA within tis-
sues, particularly the brain. In a therapeutic perspective in
which the goal is precisely to lower VLCFA levels in the brain
from ALD patients, our data support that one must be cau-
tious on using statins in ALD patients. Additional experimen-
tal data will clarify whether these drugs may have eventually
bene¢cial e¡ects on brain VLCFA concentrations in ALD
mice at di¡erent dosages than those used in this study.
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